

11th Annual Gastroenterology & Hepatology Symposium

--
February 22-23, 2019 ☯ Anaheim, CA



Case discussions for de-escalation of therapy in IBD



Sunhee Park, MD
Assistant Clinical Professor
Department of Gastroenterology

Outline

- Why consider therapy de-escalation?
- 5-ASA therapy de-escalation or cessation
- Withdrawal of immunomodulator:
 - Monotherapy
 - Combination therapy
- Withdrawal of anti-TNF therapy
- Re-treatment after therapy discontinuation

Why consider therapy de-escalation?

5-ASA therapy de-escalation or cessation

Immunomodulator de-escalation

Withdrawal of anti-TNF therapy

Re-treatment after therapy discontinuation

Factors involved in decision to de-escalate drug therapy in IBD

Thank You
sandrasp@uci.edu